Top ▲

Eosinophilic esophagitis

Disease ID:1195
Name:Eosinophilic esophagitis
Associated with:0 target
1 immuno-relevant ligand
Description
An esophagitis characterized by inflammation resulting from eosinophil activity in the esophagus.
Database Links
Disease Ontology: DOID:13922
Orphanet: ORPHA73247

Targets

No target related data available for Eosinophilic esophagitis

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
dectrekumab
Immuno Disease Comments: Phase 2 trial NCT01022970 in eosinophilic esophagitis has been completed.
Clinical Use: Dectrekumab (QBX258) reached Phase II clinical trial as a potential biologic therapy for several immune conditions, including idiopathic pulmonary fibrosis (IPF), asthma, eosinophilic esophagitis [1] (proof of principle study NCT01022970), Crohn's disease, keloids and allergic rhinitis. As of May 2017, there are no active dectrekumab studies. | View clinical data

References

Show »

1. Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A et al.. (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J. Allergy Clin. Immunol., 135 (2): 500-7. [PMID:25226850]